Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says

MT Newswires Live09-25 23:12

Charles River Laboratories' (CRL) Discovery and Safety Assessment segment faces the largest margin upside, as pricing has not been meaningfully factored in, RBC Capital Markets analysts said in a Friday note.

Analysts said the company's long-range plan beat consensus expectations but was in line with RBC estimates.

The company believes integrating in vitro, in silico, and in vivo evidence to generate more robust decision-making is the future of new approach methodologies, according to RBC.

Analysts said that the company's $300 million Create the Future program is a credible margin bridge, while manufacturing expansion expands its reach across the clinical development life cycle.

RBC retained an outperform rating on the stock and increased its price target to $322 from $282.

Price: 291.92, Change: -2.52, Percent Change: -0.86

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2670425381?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670425381","market":"sg","top_or_hot":-1,"title":"Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Charles River Laboratories' (CRL) Discovery and Safety Assessment segment faces the largest margin upside, as pricing has not been meaningfully factored in, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said the company's long-range plan beat consensus expectations but was in line with RBC estimates.</p><p>The company believes integrating in vitro, in silico, and in vivo evidence to generate more robust decision-making is the future of new approach methodologies, according to RBC.</p><p>Analysts said that the company's $300 million Create the Future program is a credible margin bridge, while manufacturing expansion expands its reach across the clinical development life cycle.</p><p>RBC retained an outperform rating on the stock and increased its price target to $322 from $282.</p><p>Price: 291.92, Change: -2.52, Percent Change: -0.86</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharles River Laboratories's DAS Segment Faces Largest Margin Upside, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-25 23:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Charles River Laboratories' (CRL) Discovery and Safety Assessment segment faces the largest margin upside, as pricing has not been meaningfully factored in, RBC Capital Markets analysts said in a Friday note.</p><p>Analysts said the company's long-range plan beat consensus expectations but was in line with RBC estimates.</p><p>The company believes integrating in vitro, in silico, and in vivo evidence to generate more robust decision-making is the future of new approach methodologies, according to RBC.</p><p>Analysts said that the company's $300 million Create the Future program is a credible margin bridge, while manufacturing expansion expands its reach across the clinical development life cycle.</p><p>RBC retained an outperform rating on the stock and increased its price target to $322 from $282.</p><p>Price: 291.92, Change: -2.52, Percent Change: -0.86</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0390134368.USD","symbol_name":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670425381","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670425381","pubTimestamp":1790349172,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Charles River Laboratories'  Discovery and Safety Assessment segment faces the largest margin upside, as pricing has not been meaningfully factored in, RBC Capital Markets analysts said in a Friday note.Analysts said the company's long-range plan beat consensus expectations but was in line with RBC estimates.The company believes integrating in vitro, in silico, and in vivo evidence to generate more robust decision-making is the future of new approach methodologies, according to RBC.Analysts said that the company's $300 million Create the Future program is a credible margin bridge, while manufacturing expansion expands its reach across the clinical development life cycle.RBC retained an outperform rating on the stock and increased its price target to $322 from $282.Price: 291.92, Change: -2.52, Percent Change: -0.86","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK4121":"生命科学工具和服务","BK7095":"多种金属与采矿","BK4530":"医药外包概念","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","CRL.AU":"Comet Resources Ltd","CRL":"查尔斯河","LU0128526141.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" ACC","LU0029874061.USD":"TEMPLETON GLOBAL SMALLER COMPANIES \"A\" YDIS INC","BK4588":"碎股","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4585":"ETF&股票定投概念"},"translate_title":"加拿大皇家银行表示，Charles River Laboratories 的 DAS 部门面临最大的利润率上涨空间","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL.AU":1,"CRL":1.5},"content_text":"Charles River Laboratories' (CRL) Discovery and Safety Assessment segment faces the largest margin upside, as pricing has not been meaningfully factored in, RBC Capital Markets analysts said in a Friday note.Analysts said the company's long-range plan beat consensus expectations but was in line with RBC estimates.The company believes integrating in vitro, in silico, and in vivo evidence to generate more robust decision-making is the future of new approach methodologies, according to RBC.Analysts said that the company's $300 million Create the Future program is a credible margin bridge, while manufacturing expansion expands its reach across the clinical development life cycle.RBC retained an outperform rating on the stock and increased its price target to $322 from $282.Price: 291.92, Change: -2.52, Percent Change: -0.86","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2670425381","isCrawlerRequest":true}